Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)

Trial Profile

An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Tc 99m tilmanocept (Primary) ; Tc 99m sulfur colloid
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
    • 04 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
    • 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top